Hledat klinickou studii
257 Výsledků
Studie přijímající pacienty
= 
; Probíhající studie = 
; Ukončená studie = 
; Financováno členem konsorcia IRDiRC = 
; Člen ERN = 
Národní klinické studie
NĚMECKO
Berlin
ADDRESS: NOT PROVIDED - DE
Sicherheit von Abatacept bei der Behandlung von interstitiellen Lungenerkrankungen (ILD) bei Patienten mit variablem Immundefekt (CVID) und ähnlichen Erkrankungen.
Institution: Information not provided - DE
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy - AT
Institution: Information not provided - AT
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies (Phase 2) - AT
Institution: Information not provided - AT
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML) - AT
Institution: Information not provided - AT
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
BRIGHT AML1019: A randomized (1:1), double-blind, multi-center, placebo controlled study evaluating intensive chemotherapy with or without Glasdegib (PF-04449913) or Azacitidine with or without Glasdegib in patients with previously untreated acute myeloid leukemia (phase 3) - AT
Institution: Information not provided - AT
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
TALAPRO-1: A phase 2, open-label, response rate study of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone acetate/prednisone) - AT
Institution: Information not provided - AT
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
HOVON 156 AML: A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy - AT
Institution: Information not provided - AT
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
HOVON 150 AML: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed AML or MDS With Excess Blasts-2, With an IDH1 or IDH2 Mutation [...] - AT
Institution: Information not provided - AT
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial (Phase 3) - AT
Institution: Information not provided - AT
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML - AT
Institution: Information not provided - AT
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 2 Study of TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations - AT
Institution: Information not provided - AT
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
A multi-center continuation study evaluating azacitidine with or without glasdegib (PF-04449913) in patients with previously untreated acute myeloid leukemia, myelodysplastic syndrome or chronic myelomonocytic leukemia (phase 3) - AT
Institution: Information not provided - AT
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 1/2, Open-label, Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia (AML) and Treatment-naïve Subjects With AML Who Are Not Eligible for Intensive Induction Chemotherapy - AT
Institution: Information not provided - AT
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
ENHANCE-3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy - AT
Institution: Information not provided - AT
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
REAL 8: A Study Comparing the Effect and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® as Well as Evaluating Long-term Safety of Somapacitan in a Basket Study Design in Children With Short Stature Either Born Small for Gestational Age or With Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature - AT
Institution: Information not provided - AT
RAKOUSKO
WIEN
WIEN
QUAZAR AML-001: A phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
RAKOUSKO
WIEN
WIEN
IDHENTIFY: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
RAKOUSKO
WIEN
WIEN
A Phase 1/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
BELGIE
ANTWERPEN
EDEGEM (ANTWERPEN)
WIDEA: Wilms' Tumor (WT1) Antigen-targeted Dendritic Cell Vaccination to Prevent Relapse in Adult Patients With Acute Myeloid Leukemia: a Multicenter Randomized Phase II Trial
Antwerp University Hospital - UZA
Antwerp University Hospital
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
CREATE (EORTC-90101): Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumor induced by causal alterations of ALK and/or MET - BE
Institution: Information not provided - BE
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
ADMIRAL: Etude de phase 3 ouverte, multicentrique, randomisée de l'ASP2215 versus une chimiothérapie de rattrapage chez des patients atteints de leucémie myéloïde aiguë récidivante ou réfractaire à mutation FLT3
Institution: Information not provided - BE
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
Une étude de phase 3, multicentrique, randomisée et ouverte portant sur la guadécitabine (SGI-110) comparée au traitement de choix chez des adultes atteints de leucémie myéloïde aiguë précédemment traitée - BE
Institution: Information not provided - BE
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
MERGE - MRX-800: Une étude visant à évaluer la sécurité à long terme du maralixibat, un inhibiteur du transporteur d'acide biliaire dépendant du sodium apical (ASBTi), dans le traitement de la maladie hépatique cholestatique chez des sujets qui ont déjà participé à une étude sur le maralixibat - BE
Institution: Information not provided - BE
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
CUV152: Une étude ouverte preuve de concept, phase IIa, visant à évaluer l'innocuité et l'efficacité des implants sous-cutanés d'afamélanotide chez des patients atteints de Xeroderma Pigmentosum C et V (XPC et XPV) - BE
Institution: Information not provided - BE
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
RISE/MRX-801: Étude ouverte de phase 2 visant à évaluer l'innocuité et la tolérabilité du maralixibat dans le traitement des nourrissons atteints de maladies hépatiques cholestatiques, y compris la cholestase intrahépatique familiale progressive et le syndrome d'Alagille - BE
Cliniques universitaires Saint-Luc - UCLouvain
Service de gastro-entérologie et hépatologie pédiatrique
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Etude de phase 2/3, randomisée, multicentrique, ouverte, à 3 bras et en 2 étapes portant sur l'ASP2215 (Gilteritinib), l'association d'azacitidine et de l'ASP2215 et l'azacitidine seule dans le traitement de patients nouvellement diagnostiqués comme atteints d'une leucémie myéloïde aiguë avec mutation FLT3, qui sont non éligibles pour une chimiothérapie d'induction intensive - BE
Cliniques universitaires Saint-Luc - UCLouvain
Department of Hematology
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EXIST-LT: étude de suivi à long terme pour surveiller la croissance et le développement de patients pédiatriques préalablement traités par l'évérolimus dans l'étude CRAD001M2301 - BE
Universitair Ziekenhuis Brussel
Pediatric neurology / Neurologie Kinderen
BELGIE
LIEGE
LIEGE
Décitabine 10 jours, fludarabine et 2 séances d'irradiation corporelle totale comme stratégie de conditionnement pour la LAM à risque élevé et très faible en CR1 (phase II)
CHU de Liège - Domaine universitaire du Sart Tilman
Department of Hematology / Hématologie clinique - CHU de Liège
BELGIE
VLAAMS BRABANT
LEUVEN
OLE-IEDAT: Open-label, langdurige extensie-studie van intra-erytrocyten Dexamethason natriumfosfaat bij patiënten met Ataxia Telangiectasia die deelnamen aan de IEDAT-02-2015-studie - BE
UZ Leuven - Campus Gasthuisberg
Laboratory of Pediatric Immunology
BELGIE
VLAAMS BRABANT
LEUVEN
CRAD001M2X02B: Etude roll-over de sécurité à long terme, ouverte et multicentrique, chez des patients présentant une sclérose tubéreuse et des convulsions réfractaires jugés par l'investigateur comme pouvant bénéficier d'un traitement continu par Everolimus après la fin de l'étude CRAD001M2304 - BE
UZ Leuven - Campus Gasthuisberg
Kinderen neurologie / Paediatric Neurology
ESTONSKO
Tartu
TARTU
Phase III study to evaluate GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
Haematology and Oncology Clinic - Tartu University Hospital
Haematology and Oncology Clinic
FINSKO
Finland
HELSINKI
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens - FI
HUS - Helsinki University Hospital
Comprehensive Cancer Center
FRANCIE
AUVERGNE-RHONE-ALPES
LYON
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - FR
CLCC Léon Bérard
Centre Léon Bérard
FRANCIE
BOURGOGNE-FRANCHE-COMTE
DIJON
SESAM : Essai de phase II en double aveugle, multicentrique et contrôlé par placebo, évaluant l'efficacité et la tolérance de l'alpelisib (BYL719) chez les enfants et les adultes atteints du syndrome de mégalencéphalie-malformation capillaire-polymicrogyrie (MCAP) -FR
CHU Dijon Bourgogne - Hôpital François Mitterrand
Centre Hospitalier Universitaire Dijon
FRANCIE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Essai clinique de phase III comparant la thérapie de conditionnement à base de Tréosulfan avec un conditionnement à intensité réduite (CIR) à base de Busulfan, préalablement à la transplantation allogénique de cellules souches hématopoïétiques, chez les patients atteints de LAM ou du syndrome myélodysplasique (SMD), considérés comme inéligibles aux régimes de conditionnement standard
Institution: Information not provided - FR
FRANCIE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Essai clinique en ouvert de phase I/IIa déterminant la dose maximale tolérée, la tolérance, la pharmacocinétique et l'efficacité du BI 6727 en intraveineux en monothérapie ou en association à la cytarabine par voie souscutanée chez des patients atteints de leucémie myéloïde aiguë.
Institution: Information not provided - FR
FRANCIE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
EXIST-2: A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) - ES (Phase III)
Institution: Information not provided - FR
FRANCIE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
EXIST-3: A Three-arm, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Two Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-onset Seizures (Phase III) - FR
Institution: Information not provided - FR
FRANCIE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
MERGE - MRX-800: A Long-Term Safety Study of Maralixibat, an Apical Sodium Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study - FR
Institution: Information not provided - FR
FRANCIE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
RISE: Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants with Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome. - Maralixibat Infant Safety Evaluation -FR
Institution: Information not provided - FR
FRANCIE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
LIBRETTO-001 : Étude de phase 1/2 évaluant selpercatinib (LOXO-292) administré par voie orale à des patients atteints de tumeurs solides avancées, y compris les tumeurs solides positives à la fusion RET, le cancer médullaire de la thyroïde et d'autres tumeurs avec activation RET -FR
Institution: Information not provided - FR
FRANCIE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
FRANCIE
ILE-DE-FRANCE
PARIS
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - FR
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Hôpital Saint Louis
FRANCIE
ILE-DE-FRANCE
PARIS
A Phase 3 Open-label Randomized Study of Quizartinib AC220 Monotherapy Versus Salvage Chemotherapy in Subjects With Feline McDonough Sarcoma FMS Like Tyrosine Kinase 3 Internal Tandem Duplication FLT3 ITD Positive Acute Myeloid Leukemia AML Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation HSCT Consolidation - FR
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Service : Centre des Maladies du Sang
FRANCIE
ILE-DE-FRANCE
PARIS
SAMBA-trial: Etude de phase II avec JNJ-56022473 en monothérapie chez les patients présentant un syndrome myélodysplasique de haut risque (IPSS int 2 et élevé) ou une leucémie aigue myéloblastique en échec d'un agent hypométhylant
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Service d'Hématologie seniors
FRANCIE
ILE-DE-FRANCE
PARIS
WAS FUP : Suivi à long terme des patients inscrits à l'essai clinique de phase I/II de thérapie génique par cellules souches hématopoïétiques dans le syndrome de Wiskott-Aldrich (GTG002-07 and GTG003-08) - FR
Hôpital Necker-Enfants Malades
Département de Biothérapie - Unité d'Hémaphérèse Thérapeutique
FRANCIE
ILE-DE-FRANCE
PARIS
FancoMob : Etude pilote évaluant la faisabilité de la mobilisation sanguine et de la collection des cellules CD34+ après traitement par G-CSF et plérixafor chez des patients atteints d'Anémie de Fanconi en vue d'un traitement ulterieur par thérapie génique (Phase I-II)
Hôpital Necker-Enfants Malades
Service d'Hématologie adulte
FRANCIE
OCCITANIE
TOULOUSE
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - FR
IUCT Oncopole - CLCC Institut Claudius Regaud
Bureau des études cliniques
FRANCIE
PAYS DE LA LOIRE
ANGERS
FRANCIE
PAYS DE LA LOIRE
NANTES
FRANCIE
PAYS DE LA LOIRE
NANTES
Randomized Open Phase III Trial Testing Efficacy of Gemtuzumab Ozogamycin (MYLOTARG) Associated to Intensive Chemotherapy for Patients Aged Between 18-60 Years and Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk
CHU de Nantes - Hôtel Dieu
Service d'hématologie clinique
FRANCIE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - FR
CLCC Institut Paoli Calmettes
Institut Paoli-Calmettes
NĚMECKO
Baden-Württemberg
FREIBURG
ABACHAI: Sicherheit und Wirksamkeit von Abatacept (s.c.) bei Patienten mit CTLA4-Insuffizienz oder LRBA-Defizienz (Studie des GAIN-Netzwerks)
CCI am Universitätsklinikum Freiburg
Centrum für Chronische Immundefizienz
NĚMECKO
Baden-Württemberg
FREIBURG
TRANSATRA: Eine Phase I/II-Studie zu Dosisfindung und Wirksamkeit von Tranylcypromine bei Patienten mit nicht-APL AML
Universitätsklinikum Freiburg
Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation
NĚMECKO
Baden-Württemberg
FREIBURG
NIFAR: Phase 1/2 Studie zur Wirksamkeit von Nivolumab beim Rezidiv der akuten myeloischen Leukämie nach allogener hämatopoetischer Stammzelltransplantation
Universitätsklinikum Freiburg
Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation
NĚMECKO
Baden-Württemberg
FREIBURG
ELEVATE: Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
Universitätsklinikum Freiburg
NĚMECKO
Baden-Württemberg
HEIDELBERG
Indikasjon, effekt og bivirkning av behandling med mTOR-hemmer hos pasienter med tuberøs sklerose i Norge og Danmark-DK
Universitätsklinikum Heidelberg
NĚMECKO
Baden-Württemberg
HEIDELBERG
ELEVATE: Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
Zentrum für Innere Medizin (Krehl-Klinik)
Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie
NĚMECKO
Baden-Württemberg
ULM
NĚMECKO
Baden-Württemberg
ULM
ELEVATE: Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
Universitätsklinikum Ulm
NĚMECKO
Baden-Württemberg
ULM
QUAZAR AML maintenance: Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase III-Studie zum Vergleich der Wirksamkeit und Sicherheit von oralem Azacitidin plus bestmögliche Unterstützende Behandlung versus bestmögliche unterstützende Behandlung als Erhaltungstherapie bei Patienten mit akuter myeloischer Leukämie mit vollständiger Remission
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
NĚMECKO
Baden-Württemberg
ULM
Die IDHENTIFY-STUDIE: Eine multizentrische, offene, randomisierte Phase III-Studie zum Vergleich der Wirksamkeit und Sicherheit von AG-221 (CC-90007) bei älteren Patienten mit fortgeschrittener AML und IDH2-Mutation
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
NĚMECKO
Baden-Württemberg
ULM
AMLSG 30-18: Randomisierte Phase III Studie zur intensiven Standardchemotherapie versus intensiver Chemotherapie mit CPX-351 bei erwachsenen Patienten mit einer neu diagnostizierten akuten myeloischen Leukämie und intermediärem bzw. ungünstigem genetischen Risiko
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
NĚMECKO
Bayern
ERLANGEN
Eine Phase III, doppelt-verblindete, Placebo-kontrollierte, multizentrische, randomisierte Studie von Pracinostat in Kombination mit Azacitidin bei Patienten >= 18 Jahre mit neu diagnostizierter akuter myeloischer Leukämie, die für die Standardinduktionschemotherapie ungeeignet ist
Universitätsmedizin Erlangen
Universitätsklinikum Erlangen
NĚMECKO
Bayern
MÜNCHEN
ELEVATE: Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
LMU Klinikum der Universität München - Campus Großhadern
LMU Klinikum
NĚMECKO
Bayern
MÜNCHEN
AARON: Eine offene Phase-II-Studie von Relatlimab (BMS-986016) mit Nivolumab (BMS-936558) in Kombination mit 5-Azacytidin zur Behandlung von Patienten mit refraktärer/rückfälliger akuter myeloischer Leukämie und neu diagnostizierten älteren Patienten mit akuter myeloischer Leukämie
LMU Klinikum der Universität München - Campus Großhadern
Medizinische Klinik und Poliklinik III
NĚMECKO
Bayern
MÜNCHEN
ABACHAI: Sicherheit und Wirksamkeit von Abatacept (s.c.) bei Patienten mit CTLA4-Insuffizienz oder LRBA-Defizienz (Studie des GAIN-Netzwerks)
Medizinische Klinik und Poliklinik IV - Standort Ziemssenstraße
Medizinische Klinik und Poliklinik IV
NĚMECKO
Bayern
MÜNCHEN
SynCoRAS: Verbesserung der synaptischen Plastizität und der kognitiven Funktion bei Störungen des RAS-Signalweges (GeNeRARe-Studie)
TUM Fakultät für Medizin
NĚMECKO
Bayern
MÜNCHEN
SynCoRAS: Verbesserung der synaptischen Plastizität und der kognitiven Funktion bei Störungen des RAS-Signalweges (GeNeRARe-Studie)
kbo-Kinderzentrum München gemeinnützige GmbH
kbo-Kinderzentrum München
NĚMECKO
Bayern
REGENSBURG
AMLSG 26-16 / AML-ViVA: Randomisierte Phase II Studie mit Sicherheits-Run-In Phase zur Evaluation von niedrig-dosiertem Azacitidin, All-trans Retinsäure und Pioglitazon im Vergleich zu standard-dosiertem Azacitidin in Patienten >=60 Jahre mit akuter myeloischer Leukämie (AML), die refraktär sind auf Standardinduktionschemotherapie
Universitätsklinikum Regensburg
Klinik und Poliklinik für Innere Medizin III
NĚMECKO
Bayern
REGENSBURG
CD-TCR-001: Eine offene, nicht randomisierte, multizentrische Dosis-Eskalations Phase-I/II-Studie mit Kontrollgruppe zur Bewertung der Sicherheit, Machbarkeit und vorläufigen Wirksamkeit von PRAME TCR-modifizierten T-Zellen, MDG1011, in Patienten mit Hochrisiko myeloischen und lymphoiden Neoplasien
Universitätsklinikum Regensburg
Klinik und Poliklinik für Innere Medizin III
NĚMECKO
Berlin
ADDRESS: NOT PROVIDED - DE
Offene, langfristige Extensionsbehandlung mit Intra-Erythrozyten-Dexamethason-Natriumphosphat bei Patienten mit Ataxia Telangiectasia, die an der IEDAT-02-2015-Studie teilgenommen haben -DE-
Institution: Information not provided - DE
NĚMECKO
Berlin
ADDRESS: NOT PROVIDED - DE
Sicherheitsstudie von AG-120 oder AG-221 in Kombination mit Induktions- und Konsolidierungstherapie bei Patienten mit neu diagnostizierter akuter myeloischer Leukämie mit IDH1- und/oder IDH2-Mutation
Institution: Information not provided - DE
NĚMECKO
Berlin
ADDRESS: NOT PROVIDED - DE
Eine multizentrische, offene, 3-armige, 2-stufige, randomisierte Phase-2/3-Studie von ASP2215 (Gilteritinib), Kombination von ASP2215 Plus Azacitidin und Azacitidin allein in der Behandlung der neu diagnostizierten akuten myeloischen Leukämie mit FLT3-Mutation bei Patienten, die nicht für eine intensive Induktionschemotherapie in Frage kommen
Institution: Information not provided - DE
NĚMECKO
Berlin
ADDRESS: NOT PROVIDED - DE
CUV156: Eine offene Proof-of-Concept-Studie der Phase IIa zur Bewertung der Sicherheit und Wirksamkeit von subkutanen Afamelanotid-Implantaten bei Patienten mit Xeroderma Pigmentosum (XP)
Institution: Information not provided - DE
NĚMECKO
Berlin
BERLIN
ELEVATE: Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
Charité - Universitätsmedizin Berlin
NĚMECKO
Hamburg
HAMBURG
ELEVATE: Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
UKE - Universitätsklinikum Hamburg-Eppendorf
NĚMECKO
Hessen
FRANKFURT AM MAIN
OLE-IEDAT: Offene, langfristige, verlängerte Behandlung mit Intra-Erythrozyten-Dexamethason-Natriumphosphat bei Patienten mit Ataxia Telangiectasia, die an der Studie IEDAT-02-2015 teilgenommen haben
Universitätsklinikum Frankfurt
Schwerpunkt Allergologie, Pneumologie und Mukoviszidose
NĚMECKO
Hessen
FRANKFURT AM MAIN
ELEVATE: Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
Universitätsklinikum Frankfurt
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
NĚMECKO
Hessen
FRANKFURT AM MAIN
Eine randomisierte Phase II/III-Studie zu DACOGEN® (Decitabine) allein oder mit JNJ-56022473 (Anti CD123) bei AML-Patienten, für die keine intensive Chemotherapie möglich ist
Universitätsklinikum Frankfurt
Universitäres Centrum für Tumorerkrankungen (UCT) Frankfurt
NĚMECKO
Niedersachsen
BRAUNSCHWEIG
Eine multizentrische, doppelblinde, randomisierte, Placebo-kontrollierte Phase III-Studie zum Vergleich von Idasanutlin (Antagonist von MDM2) plus Cytarabin versus Cytarabin plus Placebo bei Patienten mit rezidivierender oder refraktärer akuten myeloischen Leukämie
Städtisches Klinikum Braunschweig - Standort Celler Straße
Klinik für Hämatologie und Onkologie
NĚMECKO
Niedersachsen
HANNOVER
ELEVATE: Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
Medizinische Hochschule Hannover
Medizinische Hochschule Hannover (MHH)
NĚMECKO
Nordrhein-Westfalen
BONN
Eine internationale, multizentrische, offene Studie zur Bewertung der Wirksamkeit und Sicherheit von zwei verschiedenen Impfregimen der Immuntherapie mit allogenen dendritischen Zellen, DCP-001, bei Patienten mit akuter myeloischer Leukämie, die mit anhaltender MRD in Remission sind
Universitätsklinikum Bonn (AöR)
Universitätsklinikum Bonn
NĚMECKO
Nordrhein-Westfalen
KÖLN
LIBRETTO-001: Eine Studie der Phase 1/2 zu oral verabreichtem LOXO-292 an Patienten mit fortgeschrittenen soliden Tumoren, einschließlich RET-Fusion-positiver solider Tumoren, medullärem Schilddrüsenkarzinom und anderer Tumoren mit RET-Aktivierung
Universitätsklinikum Köln
Klinik I für Innere Medizin
NĚMECKO
Rheinland-Pfalz
MAINZ
NĚMECKO
Sachsen
DRESDEN
ETAL3-ASAP: Phase III Studie zu Cytarabine und Mitoxantrone als Induktionstherapie vor SZT bei AML
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation
NĚMECKO
Sachsen
DRESDEN
HINKL: Eine randomisierte, kontrollierte Phase-2 Studie zum Wirksamkeitsnachweis der Immuntherapie mit haploidenten natürlichen Killerzellen bei Hochrisiko akuter myeloischer Leukämie
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Nationales Centrum für Tumorerkrankungen Dresden
NĚMECKO
Sachsen
DRESDEN
ELEVATE: Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
NĚMECKO
Sachsen
LEIPZIG
DELTA: Randomisierte Placebo-kontrollierte Phase-II-Studie zu Decitabin/Azacitidin in Kombination mit oder ohne Eltrombopag bei Patienten mit akuter myeloischer Leukämie = / > 65 Jahre, für die eine intensive Chemotherapie nicht in Frage kommt
Universitätsklinikum Leipzig AöR
Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie
NĚMECKO
Sachsen
LEIPZIG
Eine internationale, multizentrische, offene Studie zur Bewertung der Wirksamkeit und Sicherheit von zwei verschiedenen Impfregimen der Immuntherapie mit allogenen dendritischen Zellen, DCP-001, bei Patienten mit akuter myeloischer Leukämie, die mit anhaltender MRD in Remission sind
Universitätsklinikum Leipzig AöR
UCCL - Universitäres Krebszentrum Leipzig
NĚMECKO
Sachsen
LEIPZIG
ELEVATE: Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
Universitätsklinikum Leipzig AöR
UCCL - Universitäres Krebszentrum Leipzig
NĚMECKO
Schleswig-Holstein
KIEL
ABACHAI: Sicherheit und Wirksamkeit von Abatacept (s.c.) bei Patienten mit CTLA4-Insuffizienz oder LRBA-Defizienz (Studie des GAIN-Netzwerks)
Universitätsklinikum Schleswig-Holstein - Campus Kiel
Klinik für Innere Medizin I
IRSKO
County Dublin
DUBLIN
A phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission - IE
Tallaght University Hospital
Department of Haematology
IZRAEL
ISRAEL
ADDRESS: NOT PROVIDED - IL
LIBRETTO-001: A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation -IL
Institution: Information not provided - IL
ITÁLIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Single Arm, Open-label Clinical Trial of Hematopoietic Stem Cell Gene Therapy With Cryopreserved Autologous CD34+ Cells Transduced With Lentiviral Vector Encoding WAS cDNA in Subjects With Wiskott-Aldrich Syndrome (WAS)
Institution: Information not provided - IT
ITÁLIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Studio di fase Ib/II per la valutazione della sicurezza e dell'efficacia di Idasanutlin in combinazione con citarabina e daunorubicina in pazienti recentemente diagnosticati con leucemia mieloide acuta (AML) e sicurezza ed efficacia di Idasanutlin nel mantenimento della prima remissione completa di AML - IT
Institution: Information not provided - IT
ITÁLIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Follow-up di studio di fase I/II sull'impiego di cellule T CaspaCide derivate da donatore familiare parzialmente compatibile sottoposto a procedura di T deplezione alfa-beta, in pazienti pediatrici affetti da disordini ematologici dopo trapianto aploidentico - IT
Institution: Information not provided - IT
ITÁLIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
ADMIRAL: Studio di fase 3 in aperto, multicentrico, randomizzato di ASP2215 vs chemioterapia di salvataggio in pazienti con leucemia mieloide acuta recidivante o refrattaria (LMA) con mutazione FLT3
Institution: Information not provided - IT
ITÁLIE
LIGURIA
GENOVA
Studio clinico multicentrico, di fase 2, open label, di estensione per valutare la sicurezza e la tollerabilita' di FBS0701 (SSP-004184) in bambini, adolescenti ed adulti con sovraccarico di ferro trasfusione-dipendente
Ospedali Galliera
S.S.D. Microcitemia, anemie congenite e dismetabolismo del ferro
ITÁLIE
LOMBARDIA
MILANO
LIBRETTO-001: Studio di fase 1/2 su LOXO-292 orale in pazienti con tumori solidi avanzati, inclusi tumori solidi-RET positivi, carcinoma midollare della tiroide e altri tumori con attivazione RET
Fondazione IRCCS Istituto Nazionale dei Tumori
S.C. Oncologia Medica 1
ITÁLIE
LOMBARDIA
MILANO
TIGET-WAS - Sperimentazione clinica di fase I / II di terapia genica con cellule staminali ematopoietiche per la sindrome di Wiskott-Aldrich
Istituto San Raffaele Telethon per la Terapia Genica - TIGET
Istituto San Raffaele Telethon per la Terapia Genica
JAPONSKO
JAPAN
ADDRESS : NOT PROVIDED - JP
Pilot study of topical medicine of rapamycin for large diffuse plexiform neurofibroma of neurofibromatosis type 1
Institution: Information not provided - JP
NIZOZEMSKO
Groningen
GRONINGEN
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI >= 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged >=66 years - NL
UMCG - Universitair Medisch Centrum Groningen
Afdeling Hematologie
NIZOZEMSKO
Noord-Holland
AMSTERDAM
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral selinexor (KPT-330) to standard induction chemotherapy in AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) in patients aged >= 66 years - NL
Amsterdam UMC, locatie VUmc
Afdeling Hematologie
NIZOZEMSKO
Zuid-Holland
LEIDEN
NIZOZEMSKO
Zuid-Holland
LEIDEN
Decitabine-cytarabine chemotherapie bij oudere AML en hoog risico MDS patiënten (> 65 jaar) met hoge kans op vroeg overlijden
LUMC - Leids Universitair Medisch Centrum
Afdeling Hematologie
NIZOZEMSKO
Zuid-Holland
ROTTERDAM
RATE trial: Gerandomiseerde open label cross-over studie naar het effect van rapamycine op moeilijk behandelbare epilepsie bij kinderen met Tubereuze Sclerose Complex (fase II/III studie)
Erasmus MC - Erasmus Medisch Centrum
Afdeling Kinderneurologie
NIZOZEMSKO
Zuid-Holland
ROTTERDAM
RAPIT trial: Onderzoek naar behandeling van leer- en gedragsproblemen bij kinderen met Tubereuze Sclerose Complex met RAD001/everolimus (fase II/III studie)
Erasmus MC - Erasmus Medisch Centrum
Afdeling Kinderneurologie
NIZOZEMSKO
Zuid-Holland
ROTTERDAM
NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL
Erasmus MC - Erasmus Medisch Centrum
Afdeling Kinderneurologie
NIZOZEMSKO
Zuid-Holland
ROTTERDAM
NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL
Erasmus MC - Erasmus Medisch Centrum
Afdeling Neurowetenschappen
ŠPANĚLSKO
Comunidad Valenciana
VALENCIA
QUAZAR AML-001: Estudio fase 3, aleatorizado, doble ciego y controlado con placebo para comparar la eficacia y la seguridad de azacitidina oral más el mejor tratamiento de apoyo frente al mejor tratamiento de apoyo como terapia de mantenimiento en pacientes con leucemia mieloide aguda en remisión completa -ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
ŠPANĚLSKO
Comunidad Valenciana
VALENCIA
IDHENTIFY: Estudio de fase 3, multicéntrico, abierto, aleatorizado para comparar la eficacia y la seguridad de AG-221 (CC-90007) en comparación con la asistencia habitual en pacientes de edad avanzada con leucemia mieloide aguda terminal que llevan una mutación de la isocitrato deshidrogenasa 2 -ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
ŠPANĚLSKO
Comunidad Valenciana
VALENCIA
QUIWI: Estudio fase II con aleatorización 2:1 para comparar la eficacia y seguridad del tratamiento con quimioterapia estándar más quizartinib frente a quimioterapia estándar más placebo en pacientes adultos con LMA de nuevo diagnóstico con el gen FLT3 no mutado -ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de Fase 2/3, multicéntrico, aleatorizado, abierto, de 3 grupos y dos etapas, de ASP2215 (Gilteritinib), la combinación de ASP2215 más azacitidina y azacitidina sola en el tratamiento de pacientes con leucemia mieloide aguda de diagnóstico reciente con mutación de FLT3 no elegibles para quimioterapia de inducción intensiva
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de fase Ib/II, abierto y aleatorizado, de dos fármacos dirigidos contra la isocitrato deshidrogenasa (IDH) mutada combinados con azacitidina: AG 120 oral más azacitidina subcutánea y AG 221 oral más azacitidina subcutánea, en sujetos con leucemia mieloide aguda recién diagnosticada portadores de una mutación IDH1 o IDH2 respectivamente [...] -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy -GB
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio aleatorizado, doble ciego, controlado con placebo, Fase 3, de Venetoclax en combinación con Azacitidina en comparación con Azacitidina, en pacientes con leucemia mieloide aguda no tratados anteriormente y no elegibles para terapias de inducción estándar -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
QuANTUM-First: Estudio de fase III, doble ciego, controlado con placebo de quizartinib (AC220) administrado en combinación con quimioterapia de inducción y consolidación, y administrado como terapia de mantenimiento a sujetos de 18 a 75 años con leucemia mielógena aguda FLT3ITD (+) de nuevo diagnóstico
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
FANCOLEN-II: Ensayo clínico en Fase II para evaluar la eficacia de la infusión de células autólogas CD34+ transducidas con un vector lentiviral portador del gen FANCA (Medicamento Huérfano) en pacientes con anemia de Fanconi subtipo A -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
PEVOLAM: Estudio fase III aleatorizado abierto para comparar el tratamiento con azacitidina más pevonedistat frente a azacitidina en adultos con LMA de nuevo diagnóstico ancianos y/o no candidatos a quimioterapia estándar de inducción
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de fase 1 de BOS172738 en pacientes con tumores sólidos avanzados con alteraciones del gen RET que incluyen cáncer de pulmón de células no pequeñas (NSCLC) y cáncer de tiroides medular (MTC) -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio aleatorizado doble ciego, y controlado con placebo de Venetoclax administrado con Citarabina a dosis bajas versus Citarabina a dosis bajas para el tratamiento de paciente naive con leucemia mieloide aguda que no son candidatos a quimioterapia intensiva -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
HOVON 150 AML: Estudio de fase 3, multicéntrico, doble ciego, aleatorizado, controlado con placebo de ivosidenib o enasidenib en combinación con terapia de inducción y terapia de consolidación seguida de terapia de mantenimiento en pacientes con leucemia mieloide aguda recién diagnosticada o síndrome mielodisplásico con exceso de blastos-2, con una mutación IDH1 o IDH2 [...] - ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
LIBRETTO-531: Un ensayo multicéntrico, aleatorizado y abierto de fase 3 que compara selpercatinib con los medicamentos cabozantinib o vandetanib, preferidos por los médicos, en pacientes con cáncer medular de tiroides progresivo y avanzado con RET mutante y sin tratamiento anterior con inhibidores de quinasa - ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de fase I/II con aumento escalonado y ampliación de la dosis, multicéntrico, abierto y con un solo grupo, para evaluar la seguridad, la tolerabilidad, las características farmacocinéticas y la actividad antitumoral de FCN-159 en participantes adultos y menores de edad con neurofibromatosis de tipo 1
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de fase 1b/2 de IMGN632 como monoterapia o en combinación con venetoclax y/o azacitidina en pacientes con leucemia mieloide aguda con valor positivo de CD123 -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Ensayo clínico de fase I-II multicéntrico y abierto para evaluar la seguridad y la tolerabilidad de la combinación de azacitidina o citarabina en dosis bajas con Venetoclax y Quizartinib en pacientes de 60 años de edad o más con nuevo diagnóstico de leucemia mieloide aguda y no candidatos a inducción estándar con quimioterapia
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
ENHANCE-2: Estudio en fase III, aleatorizado, abierto, para evaluar la seguridad y la eficacia de magrolimab en combinación con azacitidina frente a la elección del médico de venetoclax más azacitidina o quimioterapia intensiva, en pacientes con leucemia mieloide aguda y TP53 mutado no tratados previamente
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de fase I/II para evaluar la seguridad, la farmacocinética y la eficacia de la administración intravenosa diaria de AB8939 en pacientes con leucemia mieloide aguda recidivante/refractaria
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Ensayo doble ciego, aleatorizado y de fase III, para evaluar la eficacia de Uproleselan administrado con quimioterapia en comparación con quimioterapia sola en pacientes con leucemia mieloide aguda recidivante/refractaria
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Seguimiento a largo plazo: estudio clínico de fase I/II para evaluar la seguridad y la eficacia de la infusión de células CD34+ autólogas transducidas con un vector lentiviral portador del gen FANCA (medicamento huérfano) en pacientes con anemia de Fanconi subtipo A
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
EPIK-P2: Estudio de fase II doble ciego con un periodo inicial aleatorizado, controlado con placebo y de 16 semanas de duración para evaluar la eficacia, la seguridad y la farmacocinética de alpelisib (BYL719) en pacientes pediátricos y adultos con síndrome de sobrecrecimiento asociado a PIK3CA -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
ENHANCE-3: Estudio en fase III, aleatorizado, con doble enmascaramiento y controlado con placebo para evaluar la seguridad y la eficacia de magrolimab frente a placebo en combinación con venetoclax y azacitidina en pacientes con leucemia mieloide aguda recién diagnosticados, no tratados previamente y que no son aptos para la quimioterapia intensiva
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de fase Ib/II, abierto, de búsqueda de dosis y expansión del inhibidor de Bcl-2 BGB-11417 en pacientes con neoplasias malignas mieloides
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de fase 1, multicéntrico, abierto, de escalada de dosis para evaluar la seguridad, tolerabilidad, farmacocinética y actividad clínica de LP-108 administrado por vía oral como monoterapia y en combinación con azacitidina en sujetos con síndromes mielodisplásicos (MDS) en recaída o refractarios, leucemia mielomonocítica crónica (CMML) o leucemia mieloide aguda (AML) -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio Fase I, abierto, de búsqueda de dosis, de CC-91633 (BMS-986397) en sujetos con Leucemia Mieloide Aguda en recaída o refractaria, o con Síndromes Mielodisplásicos de alto riesgo en recaída o refractarios
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
LAVA: Estudio sin enmascaramiento de fase 1 y 2a para evaluar la seguridad, la tolerabilidad, la farmacocinética, la farmacodinámica, la inmunogenicidad y la actividad antitumoral de LAVA-051 en pacientes con leucemia linfocítica crónica, mieloma múltiple o leucemia mieloide aguda con CD1d positivo recidivantes o refractarios
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de fase I, abierto, no aleatorizado, no comparativo, multicéntrico, que evalúa S65487, un inhibidor de Bcl-2 administrado por vía intravenosa, en pacientes con leucemia mieloide aguda recidivante o refractaria, linfoma no Hodgkin, mieloma múltiple o leucemia linfocítica crónica
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Un estudio de fase I/II de NMS-03592088, un inhibidor de FLT3, KIT y CSF1R, en pacientes con LMA o LMMC recaída o refractaria
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de fase 1, abierto, de búsqueda de dosis de CC-95251 solo y en combinación con agentes antineoplásicos en sujetos con leucemia mieloide aguda y síndromes mielodisplásicos
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio preliminar de fase IIa, sin enmascaramiento, para evaluar la seguridad y la eficacia de los implantes subcutáneos de afamelanotida en pacientes con xerodermia pigmentosa C y V (XPC y XPV) -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Ensayo de fase I/II abierto y multicéntrico de GEN3014 (HexaBody-CD38) en mieloma múltiple recidivante o resistente al tratamiento y otras neoplasias hematológicas malignas
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
LIBRETTO-001: Estudio en fase I de LOXO-292 oral en pacientes adultos con tumores sólidos en estadio avanzado, lo que incluye el cáncer de pulmón no microcítico con gen de fusión RET, el cáncer medular de tiroides y otros tumores con aumento de la actividad de RET -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
TrustTSC: Ensayo en fase III, doble ciego, aleatorizado y controlado con placebo del tratamiento adyuvante con ganaxolona (GNX) en niños y adultos con epilepsia relacionada con el complejo de esclerosis tuberosa (CET) -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
EstuEla2022: Tratamiento, con extracto de cannabis de espectro completo, de la epilepsia refractaria asociada a complejo Esclerosis Tuberosa (CET) -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
ITCC-092; Estudio de fase Ib de Vyxeos® (daunorrubicina y citarabina liposomal) en combinación con clofarabina para el tratamiento de la leucemia mieloide aguda recidivante o refractaria en pacientes pediátricos -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Ensayo prospectivo, aleatorizado, doble ciego, controlado con placebo y multicéntrico de fase IIb para evaluar la eficacia y seguridad del mocravimod como tratamiento adyuvante y de mantenimiento en la leucemia mieloide aguda (LMA) en pacientes adultos sometidos a un trasplante alogénico de células madre hematopoyéticas (TCMH) -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
MADRID
Ensayo clínico abierto, Fase II para evaluar la eficacia y seguridad del uso de eltrombopag en niños y adolescentes con Anemia de Fanconi -ES
Hospital Infantil Universitario Niño Jesús
Servicio de Hematología y Hemoterapia
ŠPANĚLSKO
Madrid
MADRID
Estudio de extensión de Venetoclax para pacientes que han completado un ensayo clínico previo de Venetoclax
Hospital Universitario Fundación Jiménez Díaz
Servicio de Hematología y Hemoterapia
ŠPANĚLSKO
Madrid
MADRID
ŠPANĚLSKO
Madrid
MADRID
OLE-IEDAT: Tratamiento de extensión a largo plazo y sin enmascaramiento usando fosfato sódico de dexametasona intraeritrocitaria en pacientes con ataxia telangiectasia que participaron en el estudio IEDAT-02-2015
Hospital Universitario La Paz
Servicio de Neurología
ŠPANĚLSKO
Madrid
MADRID
Efectos de N-acetil-L-leucina en la Ataxia-Telangiectasia; un ensayo en fase II multinacional, multicéntrico, sin enmascaramiento para los pacientes y con enmascaramiento para los evaluadores -ES
Hospital Universitario La Paz
Servicio de Neurología infantil
ŠVÉDSKO
Region Skåne
LUND
plexifpc - Treatment of NF1-related Plexiform Neurofibroma With Trametinib; a Single Arm, Open-label Trial With the Goals of Volumetric Partial Remission and Pain Relief - SE
Skånes Universitetssjukhus
Skåne University Hospital
ŠVÝCARSKO
Suisse Alémanique
LUZERN
ŠVÝCARSKO
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.-GB
Institution: Information not provided - CH
ŠVÝCARSKO
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively [...] - CH
Institution: Information not provided - CH
ŠVÝCARSKO
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia - CH
Institution: Information not provided - CH
SPOJENÉ KRÁLOVSTVÍ
Cambridgeshire
CAMBRIDGE
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma-GB
Addenbrooke's Hospital
Addenbrookes Hospital
SPOJENÉ KRÁLOVSTVÍ
Glasgow
GLASGOW
MyeChild 01: International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy - UK
Royal Hospital For Children, NHS Greater Glasgow & Clyde
Paediatrics (Ground Floor, Zone 1)
SPOJENÉ KRÁLOVSTVÍ
Greater London
LONDON
A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
SPOJENÉ KRÁLOVSTVÍ
Greater London
LONDON
Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders-GB
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
SPOJENÉ KRÁLOVSTVÍ
Greater London
LONDON
Long Term Safety Follow up of Patients Enrolled in the Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome (GTG002-07 and GTG003-08) - GB
Great Ormond Street Hospital
Molecular and Cellular Immunology Unit
SPOJENÉ KRÁLOVSTVÍ
Greater London
LONDON
CREATE (EORTC 90101): Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET - UK
UCLH NHS Foundation Trust - University College Hospital
The London Sarcoma Service
SPOJENÉ KRÁLOVSTVÍ
Greater London
LONDON
MCRN007: An Open-label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Faslodex (Fulvestrant) in Girls With Progressive Precocious Puberty Associated With McCune-Albright Syndrome (phase II)
University College London Hospitals, NHS Foundation Trust
Endocrinology Department
SPOJENÉ KRÁLOVSTVÍ
Greater London
SURREY
A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies -GB
The Royal Marsden
Royal Marsden NHS Foundation Trust
SPOJENÉ KRÁLOVSTVÍ
Greater Manchester
MANCHESTER
A phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission - UK
The Christie, NHS Foundation Trust
The Christie NHS Foundation Trust
SPOJENÉ KRÁLOVSTVÍ
Nottinghamshire
NOTTINGHAM
AML18: A Trial for Older Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome (Phase III) - UK
LAM Action Nottingham, Voluntary Action Centre
Department of Haematology
SPOJENÉ KRÁLOVSTVÍ
Oxfordshire
OXFORD
A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies
Churchill Hospital
Department of Haematology
SPOJENÉ KRÁLOVSTVÍ
South Glamorgan
CARDIFF
Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia-GB
University Hospital of Wales
Department of Haematology
SPOJENÉ STÁTY
Ohio
CINCINNATI
Quercetin in Children With Fanconi Anemia; a Pilot Study (Phase 1) - US
Cincinnati Children's Hospital Medical Center
Department of Pediatry
SPOJENÉ STÁTY
Pennsylvania
PHILADELPHIA
Reinstituting Natural Killer Cell Cytotoxicity and Cytoskeletal Dynamics in Wiskott-Aldrich Syndrome With IL-2 Therapy (Phase 1) - US
The Children's Hospital of Philadelphia
Department of Allergy and Asthma
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
A Randomized Double-Blind Controlled Trial of Everolimus in Children and Adolescents With PTEN Mutations (RAD001XUS257T)
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex (PREVeNT Trial) A Randomized, Double-blind, Placebo-controlled Seizure Prevention Clinical Trial for Infants With TSC
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
Institution: Information not provided - US
FRANCIE
AUVERGNE-RHONE-ALPES
LYON
Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP) - FR
Hospices Civils de Lyon
FRANCIE
ILE-DE-FRANCE
BOBIGNY
Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP) - FR
CHU Paris Seine-Saint-Denis - Hôpital Avicenne
FRANCIE
ILE-DE-FRANCE
PARIS
Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP) - FR
AP-HP.Sorbonne Université - Hôpital Saint-Antoine
CHU Paris Est - Hôpital Saint-Antoine
NIZOZEMSKO
Gelderland
NIJMEGEN
Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI
Radboudumc - Radboud universitair medisch centrum
Afdeling Tumor Immunologie
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio aleatorizado, doble ciego, controlado con placebo sobre la eficacia, seguridad y tolerabilidad de las cápsulas gastrorresistentes de EPA-FFA en pacientes con poliposis adenomatosa familiar (FAP) -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Timely: Evaluación del sistema de inteligencia artificial (Gi-Genius) para la detección de adenoma en el síndrome de Lynch. Un ensayo aleatorizado, paralelo, multicéntrico y controlado -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio fase 1b para evaluar la seguridad y la eficacia de JNJ-64251330, un inhibidor Janus quinasa (JAK), en sujetos con poliposis adenomatosa familiar
Institution: Information not provided - ES
ŠPANĚLSKO
Navarra
PAMPLONA
CaPP3 Spain: Ensayo de no inferioridad, aleatorizado, doble ciego, de una dosis diaria de 600mg, 300mg o 100mg de aspirina con cubierta entérica, como prevención del cáncer en pacientes portadores de un defecto genético germinal en genes reparadores de errores de la replicación, síndrome de Lynch. Proyecto 3 del Programa de Prevención del Cancer
Hospital Universitario de Navarra
Servicio de Genética
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
Institution: Information not provided - US
Nadnárodní klinické studie
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases
Institution: Information not provided - AT
ŠVÝCARSKO
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A randomized, double-blinded, regimen controlled, phase II, multicenter study to assess the efficacy and safety of two different Vismodegib regimens in patients with multiple Basal Cell Carcinoma
Institution: Information not provided - CH
AUSTRÁLIE
Victoria
ADDRESS: NOT PROVIDED - AU
A phase II study of trametinib in paediatric, adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas
Institution: Information not provided - AU
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
CREATE: Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumor induced by causal alterations of ALK and/or MET
Institution: Information not provided - BE
FRANCIE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial
Institution: Information not provided - FR
FRANCIE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
ENFORCE: A Phase IIb Trial Evaluating Efficacy and Tolerability of GRASPA Plus Low-dose Cytarabine vs Low-dose Cytarabine Alone, in Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Patients, Over 65 Years, Unfit for Intensive Chemotherapy
Institution: Information not provided - FR
FRANCIE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Phase I dose-escalation study of the orally administrered selective Bcl-2 inhibitor S055746 as monotherapy for the treatment of patients with Acute Myeloid Leukaemia (AML) or high or very high risk Myelodysplastic Syndrome (MDS)
Institution: Information not provided - FR
FRANCIE
ILE-DE-FRANCE
EVRY
WAS FUP : Long Term Safety Follow up of Patients Enrolled in the Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome (GTG002-07 and GTG003-08)
Généthon
Centre de Recherche Généthon
FRANCIE
ILE-DE-FRANCE
PARIS
NĚMECKO
Berlin
ADDRESS: NOT PROVIDED - DE
AMLSG 16-10: Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication
Institution: Information not provided - DE
NĚMECKO
Berlin
ADDRESS: NOT PROVIDED - DE
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens
Institution: Information not provided - DE
NĚMECKO
Berlin
ADDRESS: NOT PROVIDED - DE
POLO-AML-2: A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination With Subcutaneous Low-dose Cytarabine vs. Placebo + Low-dose Cytarabine in Patients >=65 Years With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy
Institution: Information not provided - DE
NĚMECKO
Berlin
ADDRESS: NOT PROVIDED - DE
An open phase I/IIa trial to investigate the maximum tolerated dose, safety, pharmacokinetics and efficacy of intraveneous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in patients with acute myeloid leukaemia
Institution: Information not provided - DE
NĚMECKO
Berlin
ADDRESS: NOT PROVIDED - DE
An Open Label, Phase I, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients >= 65 Years With Acute Myeloid Leukemia
Institution: Information not provided - DE
NĚMECKO
Hessen
WIESBADEN
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
AbbVie Deutschland GmbH & Co. KG
IRSKO
County Dublin
ADDRESS: NOT PROVIDED - IE
CUV152: A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients With Xeroderma Pigmentosum C and V (XPC and XPV).
Institution: Information not provided - IE
ITÁLIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study
Institution: Information not provided - IT
NIZOZEMSKO
Groningen
GRONINGEN
HO155: A Randomized Phase II Multicenter Study to Assess the Tolerability and Efficacy of the Addition of Midostaurin to 10-day Decitabine Treatment in Unfit Adult Acute Myeloid Leukemia and High Risk Myelodysplasia Patients
UMCG - Universitair Medisch Centrum Groningen
NIZOZEMSKO
Utrecht
ADDRESS: NOT PROVIDED - NL
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
Institution: Information not provided - NL
NIZOZEMSKO
Utrecht
ADDRESS: NOT PROVIDED - NL
ADVANCE II: An International, Multicentre, Open-label Study To Evaluate The Efficacy and Safety of Two Different Vaccination Regimens of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia That Are In Remission With Persistent MRD
Institution: Information not provided - NL
NORSKO
Østlandet
ADDRESS: NOT PROVIDED - NO
CLAVELA: A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia
Institution: Information not provided - NO
ŠVÉDSKO
Region Stockholm
ADDRESS: NOT PROVIDED - SE
Taste and Palatability of Orfadin Suspension. An Open, Non-controlled 3 Day Study in Pediatric Patients With Hereditary Tyrosinemia Type 1 Treated With Orfadin.
Institution: Information not provided - SE
ŠVÉDSKO
Region Stockholm
ADDRESS: NOT PROVIDED - SE
A Phase 1/2, Open-Label, Multi-Center Dose Escalation, Safety and Tolerability Study of AKN-028 in Patients with Acute Myelogenous Leukemia (AML)
Institution: Information not provided - SE
ŠVÝCARSKO
Suisse Alémanique
BASEL
EXIST-2: Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Novartis International AG
ŠVÝCARSKO
Suisse Alémanique
BASEL
ŠVÝCARSKO
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A multi-centre, open-label, phase 1/1b study of escalating doses of RO5503781 administered orally as 1) a single agent, 2) in combination with cytarabine, or 3) with cytarabine and anthracycline and 4) assessing pk and safety of new optimized formulation of RO5503781 with cytarabine in patients with acute myelogenous leukemia (AML)
Institution: Information not provided - CH
ŠVÝCARSKO
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A phase Ib/II study to evaluate the safety and efficacy of vismodegib in relapsed/refractory acute myelogenous leukemia (AML) and relapsed/refractory high-risk myelodysplastic syndrome (MDS)
Institution: Information not provided - CH
ŠVÝCARSKO
Suisse Romande
ADDRESS: NOT PROVIDED - CH
EXIST-LT: Long-term follow-up study to monitor the growth and development of pediatric patients previously treated with everolimus in study CRAD001M2301
Institution: Information not provided - CH
ŠVÝCARSKO
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.
Institution: Information not provided - CH
ŠVÝCARSKO
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase IB/II Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Institution: Information not provided - CH
ŠVÝCARSKO
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients =18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy
Institution: Information not provided - CH
ŠVÝCARSKO
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Institution: Information not provided - CH
SPOJENÉ KRÁLOVSTVÍ
Greater London
ADDRESS: NOT PROVIDED - GB
MDS/AML Eltrombopag: a phase I/II study of Eltrombopag in thrombocytopenic subjects with advanced MyeloDysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS
Institution: Information not provided - GB
SPOJENÉ KRÁLOVSTVÍ
Greater London
ADDRESS: NOT PROVIDED - GB
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Institution: Information not provided - GB
SPOJENÉ KRÁLOVSTVÍ
Greater London
ADDRESS: NOT PROVIDED - GB
A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Institution: Information not provided - GB
SPOJENÉ KRÁLOVSTVÍ
Greater London
ADDRESS: NOT PROVIDED - GB
A single arm Phase I/II study of the safety and efficacy of gene-modified WT1 TCR therapy in patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) who have failed to achieve or maintain an IWG defined response following hypomethylating agent therapy
Institution: Information not provided - GB
SPOJENÉ KRÁLOVSTVÍ
Greater Manchester
ADDRESS: NOT PROVIDED - UK
SEAMLESS: A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Institution: Information not provided - UK
SPOJENÉ STÁTY
California
FOSTER CITY
MERGE - MRX-800: A Long-Term Safety Study of Maralixibat, an Apical Sodium Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study
Mirum Pharmaceuticals, Inc.
SPOJENÉ STÁTY
California
PLEASANTON
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
Astex Pharmaceuticals, Inc
SPOJENÉ STÁTY
California
PLEASANTON
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies (Phase II)
Astex Pharmaceuticals, Inc
SPOJENÉ STÁTY
New Jersey
EDISON
QuANTUM First: A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Daiichi Sankyo Pharma Development
SPOJENÉ STÁTY
New Jersey
RARITAN
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia
Janssen Research & Development, LLC
Janssen Research & Development, LLC.
SPOJENÉ STÁTY
New York
NEW YORK
SPOJENÉ STÁTY
Texas
HOUSTON
Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders
Bellicum Pharmaceuticals, Inc.
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602)
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
QUAZAR AML maintenance: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best-supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3 Open-label Randomized Study of Quizartinib AC220 Monotherapy Versus Salvage Chemotherapy in Subjects With Feline McDonough Sarcoma FMS Like Tyrosine Kinase 3 Internal Tandem Duplication FLT3 ITD Positive Acute Myeloid Leukemia AML Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation HSCT Consolidation
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
SOPRA: A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) versus Specified Physician's Choice in Patients 60 Years and older with Relapsed/Refractory Acute Myeloid Leukemia (AML) Who are Ineligible for Intensive Chemotherapy and/or Transplantation
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
IDHENTIFY: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
A Randomized Phase 2 Study of DACOGEN® (Decitabine) Plus JNJ-56022473 (Anti-CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML who are not Candidates for Intensive Chemotherapy
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
A Phase I Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With Acute Myeloid Leukemia
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
CASCADE: A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia.
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
RISE: Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants with Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome. - Maralixibat Infant Safety Evaluation.
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies - EP0042-101
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A multinational, multi-center, open-label, rater-blinded Phase II study - IB1001-203
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
EPIK-P2: A Phase II Double-blind Study With an Upfront, 16-week Randomized, Placebo-controlled Period, to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
LIBRETTO-001: A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation.
Institution: Information not provided - US
NĚMECKO
Berlin
ADDRESS: NOT PROVIDED - DE
Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP)
Institution: Information not provided - DE
ŠVÝCARSKO
Suisse Alémanique
BASEL
An open-label, randomized phase II/III-study to compare the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL) (coordination)
Novartis Pharma Services AG
SPOJENÉ KRÁLOVSTVÍ
Greater London
ADDRESS: NOT PROVIDED - GB
EPA-Pol-04: Randomised, double-blind, placebo-controlled study of the, efficacy, safety and tolerability of EPA-FFA gastro-resistant capsules, in patients with familial adenomatous polyposis (FAP).
Institution: Information not provided - GB
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US